L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lytix Biopharma AS
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Interest Income Expense
kr8.9m
CAGR 3-Years
143%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Interest Income Expense
-kr7.2m
CAGR 3-Years
2%
CAGR 5-Years
-20%
CAGR 10-Years
-10%
B
Bergenbio ASA
OSE:BGBIO
Interest Income Expense
kr9m
CAGR 3-Years
26%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Interest Income Expense
kr9.6m
CAGR 3-Years
593%
CAGR 5-Years
199%
CAGR 10-Years
22%
N
Nykode Therapeutics ASA
OSE:NYKD
Interest Income Expense
$11m
CAGR 3-Years
140%
CAGR 5-Years
178%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Interest Income Expense
kr1.6m
CAGR 3-Years
N/A
CAGR 5-Years
-29%
CAGR 10-Years
-3%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Interest Income Expense?
Interest Income Expense
8.9m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Interest Income Expense amounts to 8.9m NOK.

What is Lytix Biopharma AS's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
46%

Over the last year, the Interest Income Expense growth was -9%. The average annual Interest Income Expense growth rates for Lytix Biopharma AS have been 143% over the past three years , 46% over the past five years .

Back to Top